Quantitative dynamic contrast-enhanced ultrasound to predict intrahepatic recurrence of hepatocellular carcinoma after radiofrequency ablation: a cohort study

References

• Global Burden of Disease Cancer C; Fitzmaurice C, Abate D, Abbasi N, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2017: a systematic analysis for the Global Burden of Disease Study. JAMA Oncol. 2019;5:1749–1768.
   PubMed Web of Science ®Google Scholar
• Bureau of Medical Administration. National Health Commission of the People’s Republic of China. Standardization for diagnosis and treatment of primary hepatic carcinom. Chin J Digest Surg. 2019;2020:1–20.
   Google Scholar
• Korean Liver Cancer Association; National Cancer Center. Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma. Gut Liver. 2019;13:227–299.
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatocellular carcinoma [published correction appears in J Hepatol. 2019 Apr;70(4):817]. J Hepatol. 2018;69:182–236.
   PubMed Web of Science ®Google Scholar
• Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases. Hepatology. 2018;68:723–750.
   PubMed Web of Science ®Google Scholar
• Hermida M, Cassinotto C, Piron L, et al. Multimodal percutaneous thermal ablation of small hepatocellular carcinoma: predictive factors of recurrence and survival in Western patients. Cancers (Basel). 2020;12:313.
   PubMed Web of Science ®Google Scholar
• Rossi S, Ravetta V, Rosa L, et al. Repeated radiofrequency ablation for management of patients with cirrhosis with small hepatocellular carcinomas: a long-term cohort study. Hepatology. 2011;53:136–147.
   PubMed Web of Science ®Google Scholar
• Yoo J, Lee MW, Lee DH, et al. Evaluation of a serum tumour marker-based recurrence prediction model after radiofrequency ablation for hepatocellular carcinoma. Liver Int. 2020;40:1189–1200.
   PubMed Web of Science ®Google Scholar
• Lee MW, Kang D, Lim HK, et al. Updated 10-year outcomes of percutaneous radiofrequency ablation as first-line therapy for single hepatocellular carcinoma < 3 cm: emphasis on association of local tumor progression and overall survival. Eur Radiol. 2020;30:2391–2400.
   PubMed Web of Science ®Google Scholar
• Ryu T, Takami Y, Wada Y, et al. Actual 10-year survival after surgical microwave ablation for hepatocellular carcinoma: a single-center experience in Japan. Ann Surg Oncol. 2019;26:4126–4133.
   PubMed Web of Science ®Google Scholar
• Canale M, Ulivi P, Foschi FG, et al. Clinical and circulating biomarkers of survival and recurrence after radiofrequency ablation in patients with hepatocellular carcinoma. Crit Rev Oncol Hematol. 2018;129:44–53.
   PubMed Web of Science ®Google Scholar
• Liu Z, Ahmed M, Sabir A, et al. Computer modeling of the effect of perfusion on heating patterns in radiofrequency tumor ablation. Int J Hyperthermia. 2007;23:49–58.
   PubMed Web of Science ®Google Scholar
• Quaia E. State of the Art: LI-RADS for Contrast-enhanced US. Radiology. 2019;293:4–14.
   PubMed Web of Science ®Google Scholar
• Fröhlich E, Muller R, Cui XW, et al. Dynamic contrast-enhanced ultrasound for quantification of tissue perfusion. J Ultrasound Med. 2015;34:179–196.
   PubMed Web of Science ®Google Scholar
• Zocco MA, Garcovich M, Lupascu A, et al. Early prediction of response to sorafenib in patients with advanced hepatocellular carcinoma: the role of dynamic contrast enhanced ultrasound. J Hepatol. 2013;59:1014–1021.
   PubMed Web of Science ®Google Scholar
• Lo GM, Al Zahrani H, Jang HJ, et al. Detection of early tumor response to axitinib in advanced hepatocellular carcinoma by dynamic contrast enhanced ultrasound. Ultrasound Med Biol. 2016;42:1303–1311.
   PubMed Web of Science ®Google Scholar
• Zhang P, Chen Y, Liu J, et al. Quantitative evaluation of combretastatin A4 phosphate early efficacy in a tumor model with dynamic contrast-enhanced ultrasound. Ultrasound Med Biol. 2018;44:840–852.
   PubMed Web of Science ®Google Scholar
• Maruyama H, Takahashi M, Shimada T, et al. Pretreatment microbubble-induced enhancement in hepatocellular carcinoma predicts intrahepatic distant recurrence after radiofrequency ablation. AJR Am J Roentgenol. 2013;200:570–577.
   PubMed Web of Science ®Google Scholar
• Kitao A, Zen Y, Matsui O, et al. Hepatocarcinogenesis: multistep changes of drainage vessels at CT during arterial portography and hepatic arteriography–radiologic-pathologic correlation. Radiology. 2009;252:605–614.
   PubMed Web of Science ®Google Scholar
• Tan L, Chen S, Wei G, et al. Sublethal heat treatment of hepatocellular carcinoma promotes intrahepatic metastasis and stemness in a VEGFR1-dependent manner. Cancer Lett. 2019;460:29–40.
   PubMed Web of Science ®Google Scholar
• Ahmed M, Solbiati L, Brace CL, et al.; Standard of Practice Committee of the Cardiovascular and Interventional Radiological Society of Europe. Image-guided tumor ablation: standardization of terminology and reporting criteria-a 10-year update. Radiology. 2014;273:241–260.
   PubMed Web of Science ®Google Scholar
• Izzo F, Granata V, Grassi R, et al. Radiofrequency ablation and microwave ablation in liver tumors: an update. Oncologist. 2019;24:e990–e1005.
   PubMed Web of Science ®Google Scholar
• Ng KKC, Chok KSH, Chan ACY, et al. Randomized clinical trial of hepatic resection versus radiofrequency ablation for early-stage hepatocellular carcinoma. Br J Surg. 2017;104:1775–1784.
   PubMed Web of Science ®Google Scholar
• Nault JC, Sutter O, Nahon P, et al. Percutaneous treatment of hepatocellular carcinoma: State of the art and innovations. J Hepatol. 2018;68:783–797.
   PubMed Web of Science ®Google Scholar
• Kang TW, Lim HK, Lee MW, et al. Aggressive intrasegmental recurrence of hepatocellular carcinoma after radiofrequency ablation: risk factors and clinical significance. Radiology. 2015;276:274–285.
   PubMed Web of Science ®Google Scholar
• Gao Y, Zheng DY, Cui Z, Ma Y, et al. Predictive value of quantitative contrast-enhanced ultrasound in hepatocellular carcinoma recurrence after ablation. WJG. 2015;21:10418–10426.
   PubMed Web of Science ®Google Scholar
• Yoshida S, Kornek M, Ikenaga N, et al. Sublethal heat treatment promotes epithelial-mesenchymal transition and enhances the malignant potential of hepatocellular carcinoma. Hepatology. 2013;58:1667–1680.
   PubMed Web of Science ®Google Scholar
• Zhang N, Wang L, Chai ZT, et al. Incomplete radiofrequency ablation enhances invasiveness and metastasis of residual cancer of hepatocellular carcinoma cell HCCLM3 via activating β-catenin signaling [published correction appears in PLoS One. 2015;10(3):e0120472]. PLoS One. 2014;9:e115949.
   PubMed Web of Science ®Google Scholar
• Dong S, Kong J, Kong F, et al. Insufficient radiofrequency ablation promotes epithelial-mesenchymal transition of hepatocellular carcinoma cells through Akt and ERK signaling pathways. J Transl Med. 2013;11:273.
   PubMed Web of Science ®Google Scholar
• Maruyama H, Sekimoto T, Yokosuka O. Role of contrast-enhanced ultrasonography with Sonazoid for hepatocellular carcinoma: evidence from a 10-year experience. J Gastroenterol. 2016;51:421–433.
   PubMed Web of Science ®Google Scholar
• Lee J, Lee JM, Yoon JH, et al. Percutaneous radiofrequency ablation with multiple electrodes for medium-sized hepatocellular carcinomas. Korean J Radiol. 2012;13:34–43.
   PubMed Web of Science ®Google Scholar
• Singh S, Siriwardana PN, Johnston EW, et al. Perivascular extension of microwave ablation zone: demonstrated using an ex vivo porcine perfusion liver model. Int J Hyperthermia. 2018;34:1114–1120.
   PubMed Web of Science ®Google Scholar
• Zhan Y, Zhou F, Yu X, et al. Quantitative dynamic contrast-enhanced ultrasound may help predict the outcome of hepatocellular carcinoma after microwave ablation. Int J Hyperthermia. 2019;35:105–111.
   PubMed Web of Science ®Google Scholar
• Wang W, Shi J, Xie WF. Transarterial chemoembolization in combination with percutaneous ablation therapy in unresectable hepatocellular carcinoma: a meta-analysis. Liver Int. 2010;30:741–749.
   PubMed Web of Science ®Google Scholar
• Peng ZW, Zhang YJ, Liang HH, et al. Recurrent hepatocellular carcinoma treated with sequential transcatheter arterial chemoembolization and RF ablation versus RF ablation alone: a prospective randomized trial. Radiology. 2012;262:689–700.
   PubMed Web of Science ®Google Scholar
• Peng ZW, Zhang YJ, Chen MS, et al. Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: a prospective randomized trial. J Clin Oncol. 2013;31:426–432.
   PubMed Web of Science ®Google Scholar
• Cao J, Dong Y, Mao F, et al. Dynamic three-dimensional contrast-enhanced ultrasound to predict therapeutic response of radiofrequency ablation in hepatocellular carcinoma: preliminary findings. Biomed Res Int. 2018;2018:6469703.
   PubMed Web of Science ®Google Scholar
• Silva MA, Hegab B, Hyde C, et al. Needle track seeding following biopsy of liver lesions in the diagnosis of hepatocellular cancer: a systematic review and meta-analysis. Gut. 2008;57:1592–1596.
   PubMed Web of Science ®Google Scholar